Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …

Diabetes promotes the development of both heart failure with a reduced ejection fraction
and heart failure with a preserved ejection fraction through diverse mechanisms, which are …

Cardiovascular (CV) disease and heart failure (HF) are the leading cause of mortality in type
2 diabetes (T2DM), a metabolic disease which represents a fast-growing health challenge …

Aim To investigate the impact of epicardial adipose tissue (EAT) thickness on
cardiopulmonary performance in patients with type 2 diabetes (T2D) and normal heart …

Obesity is considered to significantly increase the risk of the development of a vast range of
metabolic diseases. However, adipogenesis is a complex physiological process, necessary …

Epicardial adipose tissue (EAT) and pericardial adipose tissue (PAT) are metabolically
active fat depots implicated in cardiovascular disease, and EAT has potential as a novel …

In recent years, SGLT2 inhibitors have become an integral part of heart failure therapy, and
several mechanisms contributing to cardiorenal protection have been identified. In this …

Cardiovascular diseases (CVDs) are a significant burden globally and are especially
prevalent in obese and/or diabetic populations. Epicardial adipose tissue (EAT) surrounding …

Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular disease and
heart failure, which highlights the need for improved understanding of factors contributing to …